External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients. Issue 7 (July 2020)

• Record Type: Journal Article
• Authors: Demirtas, Coskun Ozer; Gunduz, Feyza; Kani, Haluk Tarik; Keklikkiran, Caglayan; Alahdab, Yesim Ozen; Yilmaz, Yusuf; Duman, Deniz Guney; Atug, Ozlen; Giral, Adnan; Aslan, Rahmi; Cagatay, Nur Sena; Ozkan, Bige; Ozdogan, Osman Cavit
• Is Part Of: European journal of gastroenterology & hepatology. Volume 32:Issue 7(2020)
• Publication Date: 2020-07
• Subjects: cirrhosis -- hepatocellular carcinoma -- surveillance -- Toronto HCC risk index; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Digestive organs -- Diseases; Liver -- Diseases; Periodicals; 616.33
• DOI: 10.1097/MEG.0000000000001685
• Languages: English
• ISSNs: 0954-691X

Abstract

Abstract : Objectives: Toronto hepatocellular carcinoma risk index is developed to stratify cirrhotic patients according to 10-year hepatocellular carcinoma risk. We aimed to validate the performance of Toronto hepatocellular carcinoma risk index in a large Turkish cohort. Materials and methods: We retrospectively reviewed the database of 1287 cirrhotic patients followed-up in a 10-year period (February 2008 to January 2018). All patients were stratified into three groups based on the Toronto hepatocellular carcinoma risk index score as follows: low-risk, < 120; intermediate risk, 120 to 240; and high risk, > 240. Area under the curve and optimal cutoff value of Toronto hepatocellular carcinoma risk index were obtained from receiver operator curve. To reveal the parameters related with hepatocellular carcinoma development, logistic regression analysis was conducted. The cumulative incidences of hepatocellular carcinoma were calculated using the Kaplan–Meier method, and the curves were compared using the log-rank test. Results: Out of 403 enrolled patients, 57 developed hepatocellular carcinoma. The median Toronto hepatocellular carcinoma risk index value was higher in hepatocellular carcinoma (+) group comparing to hepatocellular carcinoma (−) group [267 (70–366) vs. 224 (36–366), P < 0.001]. Out of 57 detected hepatocellular carcinomas, 45 (78.9%) were high risk, 11 (19.3%) were intermediate risk, and only one (1.8%) was low risk at the entry. The area under the curve of the Toronto hepatocellular carcinoma risk index to predict hepatocellular carcinoma was 0.750 (95% confidence interval, 0.683–0.817, P < 0.001). The optimal cutoff value of Toronto hepatocellular carcinoma risk index was 239.5, giving a sensitivity of 78.9% and specificity of 62.7%. As a result, Toronto hepatocellular carcinoma risk index remained to be the only significant parameter that has an affect on hepatocellular carcinoma development [adjusted-odds ratio: 1.016 (95% confidence interval, 1.007–1.024), P <0.001]. Conclusion: The present study validated the performance of Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients to predict hepatocellular carcinoma risk, which can be considered as a tool for personalized surveillance. Abstract : Supplemental Digital Content is available in the text.